A survey of physicians’ treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries

Abstract

This survey provides valuable insight into reasons for, and challenges to, the use of EHL products in clinical practice. Physicians perceived that switching to treatment with rFVIIIFc or rFIXFc can improve quality of life, treatment burden, disease control and adherence.